$210 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 51 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | $9,707,000 | -10.2% | 31,330 | 0.0% | 4.61% | +11.2% | |
| ALXN | Alexion Pharmaceuticals Inc | $8,700,000 | -14.2% | 81,641 | 0.0% | 4.14% | +6.2% | |
| LGND | Ligand Pharmaceuticals Inc | $7,363,000 | +1.6% | 35,000 | 0.0% | 3.50% | +25.7% | |
| BMRN | Biomarin Pharmaceutical Inc | $7,234,000 | -21.1% | 97,284 | 0.0% | 3.44% | -2.3% | |
| HALO | Halozyme Therapeutics Inc | $5,969,000 | -17.4% | 428,633 | 0.0% | 2.84% | +2.2% | |
| ADMS | Adamas Pharmaceuticals Inc | $5,672,000 | -40.6% | 370,000 | 0.0% | 2.70% | -26.5% | |
| KALV | Kalvista Pharmaceuticals Inc | $5,467,000 | +109.3% | 322,436 | 0.0% | 2.60% | +159.0% | |
| GILD | Gilead Sciences Inc | $5,346,000 | -16.4% | 90,284 | 0.0% | 2.54% | +3.5% | |
| ABMD | Abiomed Inc | $4,553,000 | -15.7% | 13,200 | 0.0% | 2.16% | +4.3% | |
| SPPI | Spectrum Pharmaceuticals Inc | $3,863,000 | -38.5% | 300,000 | 0.0% | 1.84% | -23.9% | |
| SHPG | Shire plcsponsored adr | $3,475,000 | -17.7% | 25,000 | 0.0% | 1.65% | +2.0% | |
| SRPT | Sarepta Therapeutics Inc | $3,344,000 | -6.3% | 27,000 | 0.0% | 1.59% | +16.0% | |
| GTHX | G1 Therapeutics Inc | $2,884,000 | -7.6% | 72,000 | 0.0% | 1.37% | +14.4% | |
| SGEN | Seattle Genetics Inc | $2,513,000 | -10.9% | 42,500 | 0.0% | 1.19% | +10.2% | |
| XENT | Intersect Ent Inc | $2,469,000 | -41.1% | 112,000 | 0.0% | 1.17% | -27.1% | |
| DCPH | Deciphera Pharmaceuticals Inc | $2,286,000 | -24.5% | 77,000 | 0.0% | 1.09% | -6.6% | |
| AGIO | Agios Pharmaceuticals Inc | $2,159,000 | -29.8% | 36,500 | 0.0% | 1.03% | -13.1% | |
| MDGL | Madrigal Pharmaceuticals Inc | $1,641,000 | -41.2% | 10,000 | 0.0% | 0.78% | -27.2% | |
| FGEN | FibroGen Inc | $1,464,000 | -25.4% | 31,400 | 0.0% | 0.70% | -7.7% | |
| SGMO | Sangamo Therapeutics Inc | $1,464,000 | -8.8% | 113,000 | 0.0% | 0.70% | +13.0% | |
| GWPH | GW Pharmaceuticals Plcads | $1,272,000 | -5.0% | 9,600 | 0.0% | 0.60% | +17.7% | |
| GMED | Globus Med Inc | $1,262,000 | -13.7% | 29,000 | 0.0% | 0.60% | +6.8% | |
| CBAY | Cymabay Therapeutics Inc | $1,231,000 | -36.7% | 145,000 | 0.0% | 0.58% | -21.7% | |
| MRUS | Merus N V | $1,136,000 | -32.9% | 75,060 | 0.0% | 0.54% | -16.9% | |
| HZNP | Horizon Pharma Plc | $1,036,000 | -9.3% | 69,000 | 0.0% | 0.49% | +12.1% | |
| SUPN | Supernus Pharmaceuticals Inc | $809,000 | -35.4% | 20,953 | 0.0% | 0.38% | -20.2% | |
| PRTK | Paratek Pharmaceuticals Inc | $766,000 | -27.1% | 103,500 | 0.0% | 0.36% | -9.9% | |
| SBPH | Spring Bk Pharmaceuticals Inc | $673,000 | -21.7% | 73,000 | 0.0% | 0.32% | -3.0% | |
| FOLD | Amicus Therapeutics Inc | $543,000 | -40.7% | 58,600 | 0.0% | 0.26% | -26.5% | |
| ONCE | Spark Therapeutics Inc | $502,000 | -49.4% | 12,000 | 0.0% | 0.24% | -37.3% | |
| RDUS | Radius Health Inc | $257,000 | -53.6% | 18,799 | 0.0% | 0.12% | -42.7% | |
| RSLS | ReShape Lifesciences Inc | $2,000 | -98.3% | 52,546 | 0.0% | 0.00% | -97.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.